Olema Pharmaceuticals, Inc. (OLMA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$52.6M
Cash & Equivalents
$46.0M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$1,040M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-05-30 | Phase1 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | PHASE3 | Recruiting | 510 |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | PHASE3 | Recruiting | 1,000 |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, ... | PHASE1 | Recruiting | 190 |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | PHASE1 | Recruiting | 180 |
| NCT05266105 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | PHASE1 | Active Not Recruiting | 60 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-05-26 | 8-K | Olema Pharmaceuticals, Inc. (OLMA) (CIK 0001750284) - EX-99.1 | EDGAR |